parkinson, Parkinson's research notebook

Six readers

reader	found	score
genetics Open Targets	no genetic evidence; overall 0.44 from other evidence	0.00
cell type Human Protein Atlas	cell type enhanced, including astrocytes; strongest in proximal tubule cells	0.75
chemistry Open Targets	a small-molecule pocket: lorecivivint	0.60
trials ClinicalTrials.gov	no Parkinson's trials on record: an open field	1.00
literature PubMed	1 Parkinson's papers of 175	0.91
pathways Reactome	in no curated pathway	0.00

No case: the score is under the bar. Receipt 0443

receipt 0449: CLK2 in dopamine neurons, braak

power: full sample -0.11 (p 0.664, n 18), 95% CI -0.55 to +0.38. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: -0.11 (p 0.664, n 18). does not hold up.
composition: dopamine neurons share of nuclei vs axis +0.05 (p 0.854); controlling for it: -0.15 (p 0.555, n 18). could be the mix.
skeptic: leave-one-out range -0.23 to +0.00, sign flips 1; without severely affected donors -0.11 (p 0.664, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLK2 in dopamine neurons.

case closed: nothing better to follow up.

receipt 0448: CLK2 in astrocytes, braak

power: full sample +0.04 (p 0.881, n 18), 95% CI -0.44 to +0.50. the interval is wide: not enough donors to tell.
confounder: adjusted for sex: +0.11 (p 0.671, n 18). does not hold up.
composition: astrocytes share of nuclei vs axis -0.21 (p 0.413); controlling for it: +0.10 (p 0.702, n 18). could be the mix.
skeptic: leave-one-out range -0.07 to +0.19, sign flips 6; without severely affected donors +0.04 (p 0.881, n 18). fragile.
cell type: no other cell group does better.
axis: no measure beats "tracks Braak Lewy-body stage" for CLK2 in astrocytes.

case closed: nothing better to follow up.

loading the receipts